PharmaCielo Begins Harvest of High-THC Cultivars for Extract Export

PharmaCielo Ltd. (or the “Company“) (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia’s premier cultivator and producer of medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S., is pleased to announce the first harvest cycle of six high-THC cultivars. The harvest from 5.5 hectares of open-air greenhouse at the company’s Rionegro complex is expected to yield more than 10 tonnes of dry flower, which will be processed at PharmaCielo’s operational processing and extraction centre (PEC) and destined for export.

Harvest of the cultivars by hand will continue to year-end, with processing commencing in coming weeks. Each of the six cultivars is unique and proprietary, developed through the horticultural expertise of the PharmaCielo team, and registered with the Colombian government.  Blending of the extracts of the cultivars delivers an unparalleled psychoactive product profile appropriate for medicinal application with the necessary and consistent high quality required.

“This first harvest of psychoactive cultivars is part of the product portfolio expansion we announced recently,” says David Attard, CEO of PharmaCielo Ltd. “As one of Colombia’s largest quota holders of government approval for the commercial processing and exporting of THC-dominant medicinal cannabis extracts, we are able to produce and deliver a variety of both CBD and now high-THC extracts including THC distillate and THC:CBD formulations based on market demand.”

As PharmaCielo moves to produce high-THC extracts in-house in its Rionegro complex, the Company continues in parallel to expand its CBD-based cultivation footprint through external growers, with the first contract already enacted in mid-August. This dual-pronged approach is being pursued to enable PharmaCielo to achieve a flexible industrial-scale production that is both cost-effective and flexible and can be scaled up as needed.